RFID technology is transforming packaging, warehousing, and supply chain operations—providing hands-free inventory tracking, automated receiving, and real-time visibility across distribution networks. As manufacturers and retailers mandate RFID compliance, packaging converters, label printers, and corrugated operations face increasing pressure to integrate RFID capability into their production lines.

This article examines the significant implications of the Drug Supply Chain Security Act on pharmacy operations. The DSCSA, designed to enhance drug supply chain security and combat counterfeit medications, presents substantial compliance challenges for pharmacy practitioners. The piece explores how pharmacies must adapt their purchasing processes, inventory management, and operational procedures to meet regulatory requirements. By addressing these impacts, the article provides valuable insights into implementation strategies and best practices that enable pharmacies to navigate the evolving regulatory landscape effectively while maintaining efficient service delivery and product integrity throughout the supply chain.

Phygital packaging represents an innovative solution to combat the growing threat of counterfeit medicines in pharmaceutical supply chains. By integrating secure physical packaging features with digital verification technologies, phygital solutions enable instant product authentication through smartphone scanning. As pharmaceutical products navigate complex distribution networks involving multiple intermediaries, maintaining control over authenticity becomes increasingly challenging. Counterfeit medicines with replicated packaging pose significant risks to patient safety and brand integrity. Phygital packaging strengthens product security, enhances supply chain transparency, and enables manufacturers to verify genuine products from factory to pharmacy. This integrated approach allows pharmaceutical companies to leverage both physical security features and digital traceability, ensuring that patients receive only legitimate medications while building consumer trust throughout the entire distribution process.

The FDA issued its first AI-related warning letter to Purolea Cosmetics Lab in April 2026, highlighting critical governance failures in regulated manufacturing. The case reveals a cascading breakdown: an AI system omitted mandatory process validation requirements, the Quality Assurance unit failed to detect this omission, and company leadership remained unaware of regulatory obligations because the AI had not communicated them. This incident underscores three fundamental failures—reliance on AI without adequate expertise, insufficient QA literacy to identify gaps, and inadequate accountability structures. The warning signals that organizations in GxP-regulated environments must strengthen their AI governance frameworks, enhance QA capability to oversee AI-generated outputs, and ensure regulatory responsibility remains with qualified human oversight rather than being delegated entirely to artificial intelligence systems.

The pharmaceutical industry faces critical pressure to ensure patient safety amid complex regulatory requirements, with counterfeit and substandard medications representing a significant global threat. The World Health Organization estimates that ten percent of medications in low- and middle-income countries are counterfeit or poor quality, while India reports five percent counterfeit and 0.3 percent spurious medicines. Robust track-and-trace solutions are essential to maintain supply chain integrity and protect public health. Without real-time tracking systems, organizations risk severe supply chain disruptions, product tampering, and inventory mismanagement. Implementing effective track-and-trace mechanisms reduces errors, minimizes waste, prevents counterfeiting, and protects brand reputation while ensuring regulatory compliance across national and international markets.

Serialization represents a critical component of modern healthcare logistics, enabling comprehensive product traceability from origin to patient. UPS Healthcare emphasizes that serialization transcends simple identification, establishing a verifiable audit trail that captures custody transfers and movement history across all supply chain partners. This end-to-end traceability ensures compliance with regulatory frameworks such as the Drug Supply Chain Security Act and GS1 standards while enhancing operational visibility and patient safety. However, implementing serialization at scale presents substantial technical challenges, requiring healthcare logistics providers to manage Electronic Product Code Information Services, Global Location Numbers, and verification processes across temperature-controlled shipments. Properly executed serialization strategies deliver regulatory compliance, supply chain control, and organizational integrity protection.

The pharmaceutical supply chain represents a critical infrastructure within healthcare, encompassing manufacturers, wholesalers, distributors, pharmacies, and healthcare providers in an interconnected network. This complex system serves three fundamental objectives: ensuring consistent drug availability to patients, reducing overall healthcare costs through operational efficiency and inventory optimization, and enhancing patient safety through stringent quality control measures. By streamlining coordination among stakeholders and implementing strategic partnerships, the supply chain minimizes unnecessary expenses while preventing shortages and overstocking. Enhanced traceability throughout the distribution process strengthens accountability and reduces medication errors, ultimately ensuring patients receive appropriate medications when needed while maintaining affordability and safety standards.

RFID technology has evolved from a niche innovation to a critical supply chain tool, driving widespread adoption across retail, manufacturing, healthcare, logistics and government sectors. Expanding RFID mandates are fundamentally reshaping product labeling, tracking and verification processes globally. Organizations increasingly rely on RFID tags for item-level tracking, inventory accuracy, loss prevention and regulatory compliance. Manufacturers must now comply with mandatory source-tagging requirements by integrating GS1 data standards and EPC Gen2v2-compliant tags into production processes. Early investment in RFID implementation enables manufacturers to maintain regulatory compliance, enhance operational efficiency and maintain competitive advantage in an evolving supply chain landscape.

Artificial intelligence is revolutionizing pharmaceutical packaging by automating quality control, ensuring regulatory compliance, and enhancing patient safety across the industry. AI-powered systems instantly detect labeling defects and packaging errors, while predictive analytics prevent equipment failures and production delays before they occur. Intelligent compliance automation ensures all regulatory requirements are met seamlessly. Smart packaging technologies deliver personalized patient instructions and medication reminders in real time. The future of pharma packaging encompasses a fully connected ecosystem with real-time production insights, transforming what has traditionally been a complex, tightly controlled process into a faster, safer, and more efficient operation that maintains brand integrity while improving overall patient outcomes.

The Drug Supply Chain Security Act (DSCSA) enforcement is now active, requiring immediate compliance from US pharmaceutical manufacturers, contract packagers, and logistics providers. Organizations must implement audit-ready serialization and traceability systems with compliant 2D Data Matrix barcodes on saleable units, establish accurate parent-child hierarchies across serialized units, cases, and pallets, and maintain enterprise-level reporting through L3/L4 systems. Critical requirements include serial number management, EPCIS event data integration, ERP connectivity, and comprehensive audit trails. With FDA enforcement underway and compliance deadlines passed, companies must urgently assess current capabilities, identify gaps, and ensure validated US packaging formats and trained operators are in place before inspections or trading partner rejections occur.

Syringe-specific constraints include needle-up particle detection, plunger obstruction of bottom illumination, reduced Tyndall utility, restricted fluid dynamics requiring higher spin speeds, and artifacts from bubbles, ribs, and fill-level assessment.Handling innovations reduce inspection noise by avoiding glass-to-glass contact, lowering vibration and bubble formation, and using controlled turnover to minimize liquid disturbance during needle-down/needle-up reorientation.

The Track-and-Trace and Serialization for Drug Market refers to the global ecosystem of technologies, software, regulatory frameworks, and services designed to monitor and document the movement of pharmaceutical products across the entire supply chain. Serialization involves assigning a unique identifier-such as a barcode or serial number-to each saleable unit of a drug, enabling precise product identification. Track-and-trace systems build on this by capturing and sharing data at every stage, from manufacturing to distribution and dispensing, ensuring full product visibility.

Most pharmaceutical operations teams understand serialization. Fewer have truly implemented aggregation correctly. And FDA inspectors know the difference. If your packaging line prints a 2D barcode on every carton but cannot tell an auditor exactly which cartons are in which cases on which pallets — in real time, from a single system — you are serialized but not aggregated. That is a compliance gap, and it is one of the most common issues Jekson Vision’s US team encounters during pre-installation assessments at pharma facilities across New Jersey, Pennsylvania, and North Carolina.

La loi sur la sécurité de la chaîne d'approvisionnement des médicaments (DSCSA) n'est plus une obligation future. Les contrôles de la FDA sont actifs, les délais sont dépassés et la marge de tolérance pour les fabricants de produits pharmaceutiques non conformes aux États-Unis se réduit rapidement. Si vous êtes un fabricant de produits pharmaceutiques, un conditionneur à façon, un CDMO ou un prestataire logistique tiers opérant aux États-Unis, cette liste de contrôle est pour vous.

A class two recall notice said that pharmacy teams should immediately stop supplying the affected batch of sertraline, quarantine all remaining stock and return it to the supplier.

Drug recalls are surprisingly common – over 14,000 recalls in the last decade in the U.S. alone – and they can be triggered by many factors. The most frequent causes include contamination and sterility failures, cGMP and manufacturing violations, labeling/packaging errors, incorrect potency (OOS), and unexpected safety issues. These recalls range from minor fixes (Class III) to life-threatening hazards (Class I). We’ll explore each top cause, real-world examples, and essential prevention steps – from implementing robust quality systems (QMS/CAPA) to using automated inspection and packaging validation. Throughout, we emphasize how advanced packaging machinery and inspection technology (like Jinlu Packing’s solutions) can dramatically reduce recall risk.

Amarox, the U.K.-unit of India’s Hetero Group, issued a voluntary recall of one batch of sertraline tablets in the United Kingdom after a patient found two different antidepressants packaged together.The recall, covering 100-mg sertraline tablets, stems from a complaint that flagged a blister strip of a separate drug, 40-mg film-coated citalopram tablets, incorrectly included in the same sealed carton. 

Pharmaceutical supply chains are among the most complex networks, encompassing numerous stakeholders such as manufacturers, distributors, pharmacies, regulators, and healthcare providers. Traditional pharmaceutical supply chains rely on manual processes, fragmented data, and limited visibility. This often causes counterfeiting, drug shortages, and misallocation of crucial medications. In recent years, digitization has emerged as a powerful solution to increase security, efficiency, and transparency in pharmaceutical supply chain management. In this blog, we explore digitalization in pharma and its impact on pharmaceutical supply chain management.

Crescent Pharma Limited is recalling one batch of Ramipril 10mg capsules as a precautionary measure. One blister pack of Ramipril 5mg capsules was found in the a sealed carton of Ramipril 10mg capsules. The MHRA has advised pharmacy and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers.

Contemporary consumers demand more than just passive experiences when shopping for products in competitive markets. Interactive packaging turns plain transactions into memorable interactions that connect with the brand. Technology integration and innovative design allow for two-way communication between brands and consumers. Traditional packaging is overlooked while interactive features draw attention, leading to increased exploration. The degree to which consumers are engaged correlates directly to brand recall, loyalty, and repurchasing over time. Companies that invest in interactive solutions experience quantifiable returns in the form of increased customer lifetime value.Understanding interaction mechanics helps companies design packaging that resonates with target audiences effectively.